Abstract: The present application relates to a compound serving as a selective PI3K? kinase inhibitor, comprising the compound shown in formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined in the description. The present application also relates to a method for using the kinase inhibitor to inhibit PI3K? kinase activity or to treat or prevent diseases or conditions associated with tyrosine kinase activity of PI3K?, as well as a use thereof.
Abstract: The present invention provides a novel pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a use or method of the compound of formula (I) in the treatment or prevention of a disorder related to the activity of RAF and/or RAS kinase.
Type:
Grant
Filed:
March 7, 2019
Date of Patent:
October 15, 2024
Assignee:
TARAPEUTICS SCIENCE INC.
Inventors:
Qing Song Liu, Jing Liu, Xi Xiang Li, Ao Li Wang, Zi Ping Qi, Qing Wang Liu, Zong Ru Jiang, Feng Ming Zou, Wen Chao Wang, Chen Hu, Cheng Chen, Li Wang
Abstract: The present invention provides a novel pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a use or method of the compound of formula (I) in the treatment or prevention of a disorder related to the activity of RAF and/or RAS kinase.
Type:
Application
Filed:
March 7, 2019
Publication date:
May 12, 2022
Applicant:
TARAPEUTICS SCIENCE INC.
Inventors:
Qing Song LIU, Jing LIU, Xi Xiang LI, Ao Li WANG, Zi Ping QI, Qing Wang LIU, Zong Ru JIANG, Feng Ming ZOU, Wen Chao WANG, Chen HU, Cheng CHEN, Li WANG
Abstract: The present application relates to a compound serving as a selective PI3K? kinase inhibitor, comprising the compound shown in formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined in the description. The present application also relates to a method for using the kinase inhibitor to inhibit PI3K? kinase activity or to treat or prevent diseases or conditions associated with tyrosine kinase activity of PI3K?, as well as a use thereof.
Abstract: An inhibitor of a wild type and Y641F mutant of human histone methyltransferase EZH2 is provided herein. Particularly, the inhibitor is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The inhibitor can be used to treat a cancer or precancerous condition related to EZH2 activity.
Type:
Grant
Filed:
January 17, 2018
Date of Patent:
May 12, 2020
Assignee:
TARAPEUTICS SCIENCE INC.
Inventors:
Qingsong Liu, Jing Liu, Fengchao Lv, Chen Hu, Wen Liang Wang, Ao Li Wang, Zi Ping Qi, Xiao Fei Liang, Wen Chao Wang, Tao Ren, Bei Lei Wang, Li Wang
Abstract: An inhibitor of a wild type and Y641 F mutant of human histone methyltransferase EZH2 is provided herein. Particularly, the inhibitor is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The inhibitor can be used to treat a cancer or precancerous condition related to EZH2 activity.
Type:
Application
Filed:
January 17, 2018
Publication date:
December 5, 2019
Applicant:
TARAPEUTICS SCIENCE INC.
Inventors:
Qingsong LIU, Jing LIU, Fengchao LV, Chen HU, Wen Liang WANG, Ao Li WANG, Zi Ping Qi, Xiao Fei LIANG, Wen Chao WANG, Tao REN, Bei Lei WANG, Li WANG
© 2025 Justia
